Literature DB >> 9547888

Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development.

A H Groll1, S C Piscitelli, T J Walsh.   

Abstract

Mesh：

Substances：

Year:  1998        PMID： 9547888     DOI： 10.1016/s1054-3589(08)60129-5

Source DB:  PubMed          Journal:  Adv Pharmacol        ISSN： 1054-3589


× No keyword cloud information.
  74 in total

Review 1.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

2.  Emerging opportunistic fungal infections: where are we heading?

Authors:  Vincent Idemyor
Journal:  J Natl Med Assoc       Date:  2003-12       Impact factor: 1.798

3.  Comparative drug disposition, urinary pharmacokinetics, and renal effects of multilamellar liposomal nystatin and amphotericin B deoxycholate in rabbits.

Authors:  Andreas H Groll; Diana Mickiene; Vidmantas Petraitis; Ruta Petraitiene; Raul M Alfaro; Christine King; Stephen C Piscitelli; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

Review 4.  Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy.

Authors:  A H Groll; H Kolve
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-11       Impact factor: 3.267

5.  Distribution of lipid formulations of amphotericin B into bone marrow and fat tissue in rabbits.

Authors:  A H Groll; D Mickiene; S C Piscitelli; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

6.  Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Joseph Meletiadis; Rafal Al-Saigh; Aristea Velegraki; Thomas J Walsh; Emmanuel Roilides; Loukia Zerva
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

7.  Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.

Authors:  Ruta Petraitiene; Vidmantas Petraitis; Andreas H Groll; Tin Sein; Robert L Schaufele; Andrea Francesconi; John Bacher; Nilo A Avila; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

8.  Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies.

Authors:  Mats O Karlsson; Irja Lutsar; Peter A Milligan
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

9.  Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis.

Authors:  Andreas H Groll; Lauren Wood; Maureen Roden; Diana Mickiene; Christine C Chiou; Ellen Townley; Luqman Dad; Stephen C Piscitelli; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

10.  Antifungal agents in current pediatric practice.

Authors:  Cecinati Valerio; Teresa Perillo; Letizia Brescia; Fabio Giovanni Russo
Journal:  Curr Infect Dis Rep       Date:  2013-06       Impact factor: 3.725
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.